Industry Update: Italfarmaco
Join us for an industry partner update as we hear from Italfarmaco on the development of Givinostat for Duchenne muscular dystrophy.
Paolo Bettica, Chief Medical Officer, and Ana Christensen, Patient Science Liaison, will discuss the Mechanism of Action of Givinostat, the preliminary results of the Phase 3 confirmatory study, and the next steps in their research and development.
Givinostat is an investigational drug. It acts as an inhibitor to allow the natural muscle repair process to work more normally. We are testing whether taking givinostat would improve muscle repair, reduce inflammation, increase regeneration and reduce fat and fibrotic replacement, for people with Duchenne muscular dystrophy (DMD). The trial enrolled boys with DMD ages 6 and older who were walking, able to climb stairs, and met other study criteria. People with any genotype could participate. A total of 179 participants enrolled at trial sites around the world. Study results will be released as part of the webinar
About Italfarmaco Group
Italfarmaco is a specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and nonprescription products in more than 60 countries on 5 continents. Italfarmaco’s research and development expertise is best demonstrated through its HDAC inhibitor development programs, addressing new therapeutic treatments of specialty and rare diseases. Through both marketed drugs and compounds in development, Italfarmaco is dedicated to serving patients whose needs remain largely unmet.